CTP emails have been hosted on Grenke’s servers since at least 2018. September 21, 2020 – Grenke AG responded to Viceroy’s report in a brief and intentionally opaque update last Friday. As far as we know, the live recording of the conference call or any
September 18, 2020 – Dear BaFin, Wolfgang Grenke issued a tepid and intentionally opaque response to Viceroy’s accusations of undisclosed related parties yesterday. The statement asserts that the supervisory board was aware of these undisclosed related parties and off-balance sheet trading entities since their inception,
Viceroy’s quick take on Grenke’s responses – and their omissions – so far. September 16, 2020 – Viceroy Research is short Grenke AG (XTRA: GLJ). You can find our original report published on Sep 15, 2020 in the following link: Grenke – For Your Fraud
Viceroy puts the spotlight on Grenke’s chicanery; swindling small businesses, laundering money for criminals, & accounting fraud. September 14, 2020 – Viceroy Research is short Grenke AG (XTRA: GLJ). Grenke’s global expansion through the purchase of dozens of undisclosed related party franchises is a fraudulent
3 July, 2020 – For posterity, please find below the infamous Zatarra Research & Investigations report on Wirecard from 2016, by Viceroy’s Fraser Perring. Four years later, this report remains entirely relevant. Weekends are bad for frauds.
May 20, 2020 – Sorrento Therapeutics’ announcement of Covid-19 “cure” follows management’s long history of unsuccessfully tailgating fads while squandering hundreds of millions in fresh investment capital. Viceroy Research are short Sorrento Therapeutics (NASDAQ:SRNE) – a biotech company with wild claims it has basically found
Not only is the factory in the wrong place, it’s not built yet November 20, 2019 – On the ground investigation of Athenex’s Chongqing factory show that the Athenex’s new API plant is not located in the Chongqing International Bio-City, and is still heavily under
Independent biotech consultants commissioned to report on Oraxol clinical data of belief Athenex will not receive New Drug Application from FDA. November 13, 2019 – Viceroy commissioned a report from a highly reputable, independent biotech consulting firm into the prospective New Drug Application (NDA) approval
Falling revenues, stalled operations, flat R&D. DOWNLOAD BRIEF November 7, 2019 – This report is a brief on Athenex’s Q3 results announcement. Viceroy will provide a further, more in depth update upon the release of Athenex’s 10-Q. Athenex revenues continue to fall Q/Q, and has
Ahead of this week’s earnings, Viceroy provide an insight of what’s to come. REPORT DOWNLOAD LINK Athenex Inc. v. Azar – Summary November 4, 2019 – This report provides a deep dive on Athenex’s significant revenue declines and capital over-commitment that investors can expect in
Viceroy Research LLC are an investigative financial research group registered in Delaware, USA.
Our research reports have been prepared for educational purposes only and expresses our opinions. Our reports and any statements made in connection with them are the authors’ opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.
To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stocks covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented “as is,” without warranty of any kind – whether express or implied.
In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using our research reports, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.
This website, all documents contained herein or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.
Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.
You should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.
The authors may continue transacting directly and/or indirectly in the securities of issuers covered herein for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.